StockpollyBeta
Get App
Popularity #3,683
ARMP · AMEX · Biotechnology

Armata Pharmaceuticals (ARMP)

Develops bacteriophage cocktails for serious antibiotic-resistant bacterial infections.

$4.20
After hours−0.02 (−0.47%)
At close$4.22(−0.94%)

  1. Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

    PRNewsWire

  2. Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

    PRNewsWireOther

  3. Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

    PRNewsWire

  4. Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

    Zacks Investment Research

  5. Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

    PRNewsWire

  6. Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

    PRNewsWire

  7. Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

    PRNewsWire

  8. Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

    PRNewsWire

  9. Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

    PRNewsWire

  10. Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.

    PRNewsWire

  11. Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

    PRNewsWire

  12. Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

    PRNewsWire

  13. Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

    PRNewsWire

  14. Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

    PRNewsWire

  15. Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy?

    Defense World

  16. Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

    PRNewsWire

  17. Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

    Zacks Investment Research

  18. Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

    PRNewsWire

  19. Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

    PRNewsWire

  20. Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

    Zacks Investment Research